ELVN,Enliven Therapeutics, Inc. | Healthcare

Healthcare

ELVN

All stocks News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Commodities

Enliven Therapeutics, Inc.ELVN

USD

- At close

USD

- Until the end

The complete list of US stocks

MAX

Overview >

Market Cap

751.24M

Revenue (ttm)

n/a

Net Income (ttm)

-89.02M

Shares Out

49.00M

EPS (ttm)

-1.89

PE Ratio

n/a

Forward PE

n/a

Dividend

n/a

Ex-Dividend Date

n/a

Volume

128,691

Open

15.06

Previous Close

14.91

Day's Range

14.45 - 15.46

52-Week Range

13.30 - 30.03

Beta

1.09

Analysts

Strong Buy

Price Target

38.20 (+149.19%)

Earnings Date

May 13, 2025

Description >

Enliven Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer.

The company's lead product candidates comprise ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial in adults with solid tumors with HER2 alterations.

Enliven Therapeutics, Inc. is headquartered in Boulder, Colorado.

Latest News >

US inflation ebbs in May as goods prices fall

Jun 28, 2024

* PCE price index flat in May; up 2.6% on year-on-year basis * Core PCE edges up 0.1%; rises 2.6% on year-on-year basis * Consumer spending gains 0.2%; personal income up 0.5% By Lucia Mutikani WASHINGTON, June 28 (Reuters) - U.S. monthly inflation was unchanged in May as a modest increase in the cost of services was offset by the...

Rocket Pharmaceuticals Says FDA Seeks More Information on Kresladi

Jun 28, 2024

10:28 AM EDT, 06/28/2024 (MT Newswires) -- Rocket Pharmaceuticals ( RCKT ) said Friday that the US Food and Drug Administration has issued a Complete Response Letter following its Biologics License Application for Kresladi to treat severe leukocyte adhesion deficiency-I. The company said the FDA requested limited additional Chemistry Manufacturing and Controls information to complete its review. Rocket said it...

European Commission To Decide On Hewlett Packard Enterprise's $14B Juniper Networks Acquisition By August 1: Details

Jun 28, 2024

The European Commission regulators are reportedly set to decide by August 1 on whether to approve Hewlett Packard Enterprise Company’s $14 billion acquisition of Juniper Networks, Inc. ( JNPR ) . Announced in January, the deal aims to enhance Hewlett Packard Enterprise’s artificial intelligence offerings and expand its networking business, reflecting the strategic focus on AI as a key growth...

Unpacking the Latest Options Trading Trends in Qualcomm

Jun 28, 2024

High-rolling investors have positioned themselves bullish on Qualcomm ( QCOM ) , and it's important for retail traders to take note. This activity came to our attention today through Benzinga's tracking of publicly available options data. The identities of these investors are uncertain, but such a significant move in QCOM often signals that someone has privileged information. Today, Benzinga's options...